- Home
- APLT vs IGC Comparison
APLT vs IGC Comparison
Compare APLT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLT | IGC |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 33.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | APLT | IGC |
|---|---|---|
| Price | $0.11 | $0.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.25 | ★ $4.13 |
| AVG Volume (30 Days) | ★ 27.2M | 496.5K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,000,000.00 | ★ $1,106,000.00 |
| Revenue This Year | $124.18 | $3.54 |
| Revenue Next Year | $66.67 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $0.25 |
| 52 Week High | $1.50 | $0.50 |
Technical Indicators
Market Signals| Indicator | APLT | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 25.08 | 47.06 |
| Support Level | $0.21 | $0.28 |
| Resistance Level | $0.26 | $0.36 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 6.69 | 56.64 |
Price Performance
Historical ComparisonAbout APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.